← Leaderboards
Louis Joseph Dell'italia
Birmingham Va Medical Center
$7,939,207
Attributed
$9,302,662
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,796,763 · 8
VA$0 · 10
By mechanism
P50$16,494,101 · 1
R01$6,884,576 · 4
U01$1,292,309 · 1
P01$880,759 · 1
T32$245,018 · 1
IS1$0 · 3
Top collaborators
- Shama Ahmad4 shared
- Victor M Darley-Usmar4 shared
- George P Yang1 shared
Most similar at Birmingham Va Medical Center
Same institution · by research overlap
- Jasvinder A Singh$1,597,683
- Chih-Chang Kevin Wei$0
Others in their field
Top investigators on “Functional Disorder”
- Randall J Bateman · Washington University$164,791,794
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- David Heimbrook · Leidos Biomedical Research, Inc.$127,725,513
- Ed Lein · Allen Institute$92,850,604
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- John M Lachin · George Washington University$85,958,868
Research focus
Functional DisorderCardiac MyocytesMediatingHeartHeart FailureCardiacChymaseMatrix MetalloproteinasesLeftMitral Valve InsufficiencyAcuteProteinsCellsProductionInsightIn VivoInterstitialIn VitroPreventStressVeteransAffectClinical TrialsLeft Ventricular Remodeling
Grant awards (58)
Genetic variation in xanthine oxidase and heart failure preserved ejection fraction$0
I01 · FY2025 · VA · contact PI
Exosome Mediated Effects on Cardiac Injury during Cardiopulmonary Bypass$0
I01 · FY2025 · VA · contact PI
Exosome Mediated Effects on Cardiac Injury during Cardiopulmonary Bypass$0
I01 · FY2024 · VA · contact PI
Allopurinol Improves Diastolic Function in African Americans with Resistant Hypertension$0
I21 · FY2024 · VA · contact PI
Genetic variation in xanthine oxidase and heart failure preserved ejection fraction$0
I01 · FY2024 · VA · contact PI
Identifying Approaches to Enhance Bone and Cartilage Regeneration$0
I01 · FY2023 · VA · contact PI
Allopurinol Improves Diastolic Function in African Americans with Resistant Hypertension$0
I21 · FY2023 · VA · contact PI
Exosome Mediated Effects on Cardiac Injury during Cardiopulmonary Bypass$0
I01 · FY2022 · VA · contact PI
Pathophysiology of Extracellular Matrix and Desmin Breakdown in Volume Overload Heart$0
I01 · FY2020 · VA · contact PI
Targeting cardiopulmonary calpains to mitigate toxicity of halogen gases.$394,553
U01 · FY2019 · ES
Chymase Ang-(1-12) Axis in Human Heart Disease$152,742
P01 · FY2019 · HL · contact PI
ShEEP Request for Next Generation High Dimension Flow Cytometer$0
IS1 · FY2019 · VA · contact PI
Pathophysiology of Extracellular Matrix and Desmin Breakdown in Volume Overload Heart$0
I01 · FY2019 · VA · contact PI
Targeting cardiopulmonary calpains to mitigate toxicity of halogen gases.$394,553
U01 · FY2018 · ES
Chymase Ang-(1-12) Axis in Human Heart Disease$180,764
P01 · FY2018 · HL · contact PI
Targeting cardiopulmonary calpains to mitigate toxicity of halogen gases.$96,525
U01 · FY2018 · ES
Pathophysiology of Extracellular Matrix and Desmin Breakdown in Volume Overload Heart$0
I01 · FY2018 · VA · contact PI
Targeting cardiopulmonary calpains to mitigate toxicity of halogen gases.$406,678
U01 · FY2017 · ES
Chymase Ang-(1-12) Axis in Human Heart Disease$173,202
P01 · FY2017 · HL · contact PI
Pathophysiology of Extracellular Matrix and Desmin Breakdown in Volume Overload Heart$0
I01 · FY2017 · VA · contact PI
ShEEP request for Live Cell Imaging with Super Resolution Microscopy$0
IS1 · FY2017 · VA · contact PI
The Chymase Angiotensin-(1-12) Axis in Heart Disease$0
I01 · FY2017 · VA · contact PI
Chymase Ang-(1-12) Axis in Human Heart Disease$170,741
P01 · FY2016 · HL · contact PI
The Chymase Angiotensin-(1-12) Axis in Heart Disease$0
I01 · FY2016 · VA · contact PI
Mitochondrial Haplotype Influences LV Dysfunction in Heart Failure$360,756
R01 · FY2015 · HL · contact PI
Chymase Ang-(1-12) Axis in Human Heart Disease$203,310
P01 · FY2015 · HL · contact PI
Single Cell Analysis of Genetic Heterogeneity in Pathogenic Cell Populations$0
IS1 · FY2015 · VA · contact PI
The Chymase Angiotensin-(1-12) Axis in Heart Disease$0
I01 · FY2015 · VA · contact PI
Mitochondrial Haplotype Influences LV Dysfunction in Heart Failure$358,925
R01 · FY2014 · HL · contact PI
The Chymase Angiotensin-(1-12) Axis in Heart Disease$0
I01 · FY2014 · VA · contact PI
Mitochondrial Haplotype Influences LV Dysfunction in Heart Failure$348,670
R01 · FY2013 · HL · contact PI
Xanthine Oxidase and Bioenergetic Function in Volume Overload$345,183
R01 · FY2013 · HL · contact PI
Chymase-Mediated MMP Activation in Ishemia Reperfusion Injury$0
I01 · FY2013 · VA · contact PI
Mitochondrial Haplotype Influences LV Dysfunction in Heart Failure$366,250
R01 · FY2012 · HL · contact PI
Xanthine Oxidase and Bioenergetic Function in Volume Overload$362,588
R01 · FY2012 · HL · contact PI
Chymase-Mediated MMP Activation in Ishemia Reperfusion Injury$0
I01 · FY2012 · VA · contact PI
Xanthine Oxidase and Bioenergetic Function in Volume Overload$366,250
R01 · FY2011 · HL · contact PI
Chymase-Mediated MMP Activation in Ishemia Reperfusion Injury$0
I01 · FY2011 · VA · contact PI
Xanthine Oxidase and Bioenergetic Function in Volume Overload$366,250
R01 · FY2010 · HL · contact PI
SCCOR in Cardiac Dysfunction and Disease$3,353,435
P50 · FY2009 · HL · contact PI
Chymase-Mediated MMP Activation in Ishemia Reperfusion Injury$0
I01 · FY2009 · VA · contact PI
SCCOR in Cardiac Dysfunction and Disease$3,226,050
P50 · FY2008 · HL · contact PI
SCCOR in Cardiac Dysfunction and Disease$3,251,049
P50 · FY2007 · HL · contact PI
Angiotensin II and Bradykinin in Cardiac Hypertrophy$343,715
R01 · FY2007 · HL · contact PI
SCCOR in Cardiac Dysfunction and Disease$3,271,519
P50 · FY2006 · HL · contact PI
Angiotensin II and Bradykinin in Cardiac Hypertrophy$353,981
R01 · FY2006 · HL · contact PI
SCCOR in Cardiac Dysfunction and Disease$3,392,048
P50 · FY2005 · HL
Angiotensin II and Bradykinin in Cardiac Hypertrophy$362,500
R01 · FY2005 · HL
TISSUE RENIN ANGIOTENSIN/CHYMASE SYSTEM IN HEART FAILURE$322,875
R01 · FY2005 · HL
Angiotensin II and Bradykinin in Cardiac Hypertrophy$387,500
R01 · FY2004 · HL
TISSUE RENIN ANGIOTENSIN/CHYMASE SYSTEM IN HEART FAILURE$322,875
R01 · FY2004 · HL
TISSUE RENIN ANGIOTENSIN/CHYMASE SYSTEM IN HEART FAILURE$322,875
R01 · FY2003 · HL
ANGIOTENSIN II AND BRADYKININ IN CARDIAC HYPERTROPHY$325,259
R01 · FY2002 · HL
TISSUE RENIN ANGIOTENSIN/CHYMASE SYSTEM IN HEART FAILURE$322,875
R01 · FY2002 · HL
TISSUE RENIN ANGIOTENSIN/CHYMASE SYSTEM IN HEART FAILURE$322,875
R01 · FY2001 · HL
ANGIOTENSIN II AND BRADYKININ IN CARDIAC HYPERTROPHY$315,786
R01 · FY2001 · HL
ANGIOTENSIN II AND BRADYKININ IN CARDIAC HYPERTROPHY$306,588
R01 · FY2000 · HL
MECHANISMS AND CONSEQUENCES OF CORONARY HEART DISEASE$245,018
T32 · FY2000 · HL